Biomanufacturing Industry Capacity Strategies Report on Developing a Flexible, Scalable and Lean System

Nov 23, 2015, 11:45 ET from ReportsnReports

PUNE, India, November 23, 2015 /PRNewswire/ --

The Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable, and Lean Biomanufacturing System Report highlights several technologies, methodologies, and business strategies that can be implemented to improve capacity and flexibility.

Complete report on biomanufacturing capacity strategies spread across 74 pages, supported with tables and figures is now available at is now available at

Biomanufacturing is common practice in the life sciences industry and has been continually developed and improved for the last two decades. However, as blockbuster drugs reach the end of their patents, treatment is evolving to become more patient-centric and personalized. The mapping of the human genome has allowed for sophisticated and effective new genetic markers and diagnostic methods to be developed, meaning that personalized medicine is becoming a reality. This has a direct impact on manufacturing, with long-term expected production paradigm shifts in the shape of near-patient manufacturing. Moreover, the rise in incidence of viral pandemics has driven a need for quick set-up, disposable, transportable biomanufacturing. This was a contributing factor to Tamiflu being first to market and will very likely be key in the race to stop the Ebola pandemic.

The report provides detailed the history of biomanufacturing development and the direction for the coming decade. The report also provides an overview of single-use bio manufacturing techniques and trends, outlining the importance of reactive biomanufacturing. It gives insight into the Ebola vaccine clinical development, as well as the validation process. The report specific capacity-enhancing approaches ranging from technology solutions to business strategy. It examines the overarching industry pressures that are driving capacity needs, the subsequent regulatory compliance, and where the biggest efficiency and productivity savings can be realized. The report explore the scale-up of bio manufacturing processes to serve commercial scale production, which is currently a major limiting factor in the maturity of this field, and how commercialization of certain therapeutics and regenerative medicines is severely limited by the lack of progression here. Order a copy of Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system - Overview report @

It ventures into the realm of lean thinking and continuous manufacturing methodologies and their application in the field of bio manufacturing with a secondary look at the potential of combining modular facilities with disposable biomanufacturing systems and the technical requirements and advances. The report details a considerable amount with regard to technology transfer and the specific issues relating to bio manufacturing, and outlines some solutions and new approaches to knowledge transfer.

It takes a wider view of the context, importance, and impact of biomanufacturing and its capacity to provide a solution to several biotechnology industry challenges. The report also provides insight into the field of personalized medicine, cell and gene therapies, and commercial-scale manufacturing vs. near-patient production and the predicted paradigm shift.

Interviews with:  

  • Tony Hitchcock, Technical Director, Cobra Biologics
  • Jerold Martin, Sr. V.P. Global Scientific Affairs, Biopharmaceuticals, Pall Corporation
  • Arnaud Schmutz, General Manager, Sourcin
  • Nigel Smart, Managing Partner, Smart Consulting Group
  • Keith Thompson, CEO, Cell Therapy Catapult
  • Results Bio manufacturing Capacity Strategies Survey

Executive Summary 

Part I of this report includes chapters 2 and 3, highlighting background information relevant to the rest of the report.

Part II of the report includes chapters 4, 5, 6, 7 and 8, which will dig deeper into specific capacity enhancing approaches ranging from technology solutions through to business strategy. Here, the report will also examine the overarching industry pressures that are driving capacity needs, the subsequent regulatory compliance and where the biggest efficiency and productivity savings can be realised.

Part III shifts slightly to take a wider view of the context, importance and impact of biomanufacturing and the capacity thereof as a solution to several Biotechnology industry challenges.

Explore other new reports by CHI Healthtech at

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

SOURCE ReportsnReports